Zobrazeno 1 - 10
of 31
pro vyhledávání: '"Marcela V Maus"'
Autor:
Nikhil C. Munshi, Christopher J. Gibson, Caron A. Jacobson, Peter Miller, Max Jan, Mark B. Leick, Geoffrey Fell, Benjamin L. Ebert, Marcela V. Maus, Elliott J. Brea, Yu-Tzu Tai, Satyen H. Gohil, Donna Neuberg, Catherine J. Wu, Adam S. Sperling
Publikováno v:
Blood Adv
Chimeric antigen receptor (CAR) T-cells have emerged as an efficacious modality in patients with non-Hodgkin lymphoma (NHL) and multiple myeloma (MM). Clonal hematopoiesis of indeterminate potential (CHIP), a state in which mutations in hematopoietic
Publikováno v:
Annual Review of Medicine. 72:365-382
Adoptive transfer of T cells modified with chimeric antigen receptors (CAR-T cells) has changed the therapeutic landscape of hematological malignancies, particularly for acute lymphoblastic leukemia and large B cell lymphoma, where two different CAR-
Autor:
Reuben Benjamin, Charlotte Graham, Deborah Yallop, Agnieszka Jozwik, Oana C Mirci-Danicar, Giovanna Lucchini, Danielle Pinner, Nitin Jain, Hagop Kantarjian, Nicolas Boissel, Marcela V Maus, Matthew J Frigault, André Baruchel, Mohamad Mohty, Athos Gianella-Borradori, Florence Binlich, Svetlana Balandraud, Fabien Vitry, Elisabeth Thomas, Anne Philippe, Sylvain Fouliard, Sandra Dupouy, Ibtissam Marchiq, Maria Almena-Carrasco, Nicolas Ferry, Sylvain Arnould, Cyril Konto, Paul Veys, Waseem Qasim, Antonio Pagliuca, Ghulam Mufti, Piers Patten, Shireen Kassam, Stephen Devereux, Majid Kazmi, Kirsty Cuthill, Victoria Potter, Andrea Kuhnl, Victoria Metaxa, Laarni Bonganay, Orla Stewart, Rose Ellard, Lorraine Catt, Jen Lewis, Farzin Farzaneh, Jackie Chappell, Alice Mason, Vicky Chu, Alan Dunlop, Adeel Saleem, Gary Cheung, Helena Munro, Elka Giemza, Oana Ciocarlie, Jan Chu, Persis Amrolia, Kanchan Rao, Robert Chiesa, Juliana Silva, Annette Hill, Maria Finch, Lindsey Young, Harvinder Hara, Sujith Samarasinghe, Anupama Rao, Ajay Vora, Kimberley Gilmour, Christine Rivat, Clare Murphy, Gulrukh Ahsan, Rasha Said Shamsah, Jesmina James, Sarah Inglott, Gary Wright, Stuart Adams, Natalia Izotova, Marina Konopleva, William Wierda, Elias Jabbour, Partow Kebrieai, Emily Jones, Kara McGee, Marcela Maus, Matthew Frigault, Jami Brown, Vesselina Toncheva, Keagan Casey, Hanno Hock, Meaghan A McKeown, Richard Mathews, Thomas Spitzer, Emmanuel Raffoux, Etienne Lengliné, Raphael Itzykson, Florence Rabian, Jérôme Larghero, Isabelle Madelaine, Elie Azoulay, Emmanuelle Clappier, Sophie Caillat-Zucman, Martine Meunier, Karine Celli-Lebras, Marie-Thérèse Tremorin, Karima Yakouben, Françoise Mechinaud-Heloury, Audrey Grain, Aurélia Alimi, Julie Roupret, Delphine Chaillou, Hélène Cavé, Aurelie Caye-Eude, Odile Fenneteau, Elodie Lainey, Jerome Naudin, Eolia Brissot, Remy Dulery, Florent Malard, Clémence Mediavilla, Agnès Bonnin, Anne Vekhoff, Tounes Ledraa, Anne Daguenel-Nguyen
Publikováno v:
The Lancet. 396:1885-1894
Summary Background Genome-edited donor-derived allogeneic anti-CD19 chimeric antigen receptor (CAR) T cells offer a novel form of CAR-T-cell product that is available for immediate clinical use, thereby broadening access and applicability. UCART19 is
Autor:
Scott J. Rodig, Mikel Lipschitz, Elizabeth Budde, Jeremy S. Abramson, Jonathon B. Cohen, Utkarsh Acharya, Michael Rogalski, Jerome Ritz, Yusuke Kamihara, Pei Hsuan Chen, Matthew J. Frigault, Stephen D. Smith, Bradley D. Hunter, Marcela V. Maus, Sarah Nikiforow, Joseph E. Maakaron, Philippe Armand, Matthew Mei, Alex F. Herrera, Robert A. Redd, Justin Kline, Ajay K. Gopal, Yi-Bin Chen, Caron A. Jacobson, Samantha Jaglowski, Kyle Wright, David G. Maloney
Publikováno v:
Journal of Clinical Oncology. 38:3095-3106
PURPOSE Axicabtagene ciloleucel (axi-cel) was approved by the Food and Drug Administration for relapsed aggressive B-cell non-Hodgkin lymphoma in part on the basis of durable remission rates of approximately 40% in a clinical trial population. Whethe
Autor:
Marcela V. Maus, Matthew J. Frigault
Publikováno v:
J Clin Invest
Cellular therapy for hematologic malignancies is a rapidly evolving field, with new iterations of novel constructs being developed at a rapid pace. Since the initial reports of chimeric antigen receptor T cell (CAR T cell)success in CD19(+) B cell ma
Autor:
Joseph S. Durgin, Fraser Henderson, MacLean P. Nasrallah, Suyash Mohan, Sumei Wang, Simon F. Lacey, Jan Joseph Melenhorst, Arati S. Desai, John Y. K. Lee, Marcela V. Maus, Carl H. June, Steven Brem, Roddy S. O’Connor, Zev Binder, Donald M. O’Rourke
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
Frontiers in Oncology
Frontiers in Oncology
Autologous chimeric antigen receptor (CAR) T cells targeted to epidermal growth factor receptor variant III (CAR T-EGFRvIII) have been developed and administered experimentally to treat patients with IDH1 wildtype recurrent glioblastoma (rGBM) (NCT02
Autor:
Karl S. Peggs, William Y. Go, Noelle V. Frey, Jennifer N. Brudno, Elena Mead, Bianca Santomasso, Rebecca Gardner, Steven Z. Pavletic, Marcelo C. Pasquini, Sattva S. Neelapu, Stephan A. Grupp, Kevin J. Curran, Frederick L. Locke, Daniel W. Lee, Cameron J. Turtle, Marcel R.M. van den Brink, Krishna V. Komanduri, Jae H. Park, Armin Ghobadi, Marcela V. Maus, John F. DiPersio, Lamis K. Eldjerou
Publikováno v:
Biology of Blood and Marrow Transplantation. 25:625-638
Chimeric antigen receptor (CAR) T cell therapy is rapidly emerging as one of the most promising therapies for hematologic malignancies. Two CAR T products were recently approved in the United States and Europe for the treatment ofpatients up to age 2
Autor:
Sarah A. Holstein, Nizar Bahlis, P. Leif Bergsagel, Manisha Bhutani, Niccolo Bolli, Carrie Brownstein, Pierre Demolis, David Foureau, Francesca Gay, Irene M. Ghobrial, Nicole Gormley, Jens Hillengass, Martin Kaiser, Marcela V. Maus, J. Joseph Melenhorst, Maximilian Merz, Michael O. Dwyer, Bruno Paiva, Marcelo C. Pasquini, Nina Shah, Sandy W. Wong, Saad Z. Usmani, Philip L. McCarthy
Publikováno v:
Transplant Cell Ther
Transplantation and cellular therapy, vol 27, iss 10
Transplantation and cellular therapy, vol 27, iss 10
The fifth annual Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Immune Profiling and Minimal Residual Disease Testing in Multiple Myeloma was conducted as one of the American Society of Hematology Annual Meeting Sc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d79ec414d86fe8eb620dacd754421351
http://hdl.handle.net/2318/1791012
http://hdl.handle.net/2318/1791012
Autor:
Matthew J. Frigault, Philip L. McCarthy, Jorg Dietrich, Shannon L. Maude, David T. Teachey, Stephan A. Grupp, Tom Whitehead, Sara Alexander, Sattva S. Neelapu, Terry J. Fry, Tomas G. Neilan, Marco L. Davila, Elena Mead, Jennifer N. Brudno, Jennifer Holter-Chakrabarty, Claudia Diamonte, Frederick L. Locke, Daniel W. Lee, Bianca Santomasso, Elizabeth J. Shpall, Julie C. Fitzgerald, Krishna V. Komanduri, Marcela V. Maus, Colleen Callahan, Michael R. Bishop, Cameron J. Turtle
Publikováno v:
Journal for immunotherapy of cancer, vol 8, iss 2
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)
Journal for Immunotherapy of Cancer
Immune effector cell (IEC) therapies offer durable and sustained remissions in significant numbers of patients with hematological cancers. While these unique immunotherapies have improved outcomes for pediatric and adult patients in a number of disea
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::78826d8095d2b25719dcc661bc8a0aef
https://escholarship.org/uc/item/0fj5p33n
https://escholarship.org/uc/item/0fj5p33n
Autor:
Marcela V. Maus
Publikováno v:
The Lancet. 398:466-467